ABSTRACT
INTRODUCTION
Senescence is a specific cellular status under a variety of stimuli with stable cell cycle arrest. Cellular senescence can be classified into replicative and premature. Replicative senescence, induced by telomere shortening during DNA replication, exists in most mammal somatic cells and is presumed to contribute to organismal aging in later adult life, while premature cellular senescence is usually induced by DNA damage, activation of oncogenic signaling, nutrition deprivation or reactive oxygen species (ROS) accumulation. Recent research compared gene expression profiles between replicative senescent cells and cells arrested by DNA damage or serum starvation and
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revealed that only a small subset of genes were exclusively regulated in replicative senescent cells while the majority of expression changes in the three conditions were similar [1] .
Cellular senescence may prevent the malignant transformation of cells through the avoidance of excessive proliferation-accumulated DNA mutations. However, in some heterogeneous tissues such as prostate, senescent stromal cells effectively support the progression of epithelium-derived cancer and are postulated as novel therapeutic targets in cancer treatment [2] . Isolated stromal fibroblasts from elderly men (63 to 81 years old), but not from young men (40 to 52 years old), have been reported to promote the proliferation of prostate epithelial cells by highly expressing CXCL12 [3] . Other research has reported the up-regulation of growth factors and chemokines in senescent prostate stromal cells, inducing the proliferation of cancer cells in a paracrine manner [4] . Recent research indicated that senescent stromal cells supported cancer cell proliferation by secreting energyrich compounds, induced epithelial-to-mesenchymal transition progression, and subsequently promoted cancer aggressiveness, as well as contributed to the immune escape of cancer cells [5] . Moreover, senescent stromal cells also enhanced the chemoresistance of cancer cells in a paracrine manner [6] . These reports suggest senescent stroma is a potential therapeutic target in prostate cancer treatment.
Ginsenoside Rg3, extracted from a traditional medical herb, ginseng, has been reported as a relatively safe drug with anticancer activity both in vitro and in vivo [7, 8] . Previous studies evaluating the effects of ginsenoside Rg3 on prostate cancer cells have revealed that the compound inhibited the proliferation and migration of cancer cells, as well as enhanced the susceptibility of cancer cells to chemotherapeutic drugs by inhibiting the NF-κB signaling pathway [9] [10] [11] . The beneficial effects of ginsenoside Rg3 on prostate cancer cells have been well recognized, while the impact of this compound on stromal cells is still ambiguous.
In this study, we report the anti-senescence role of ginsenoside Rg3 in prostate stromal cells pre-incubated in medium with low serum concentration. Our results suggest that ginsenoside Rg3 also regulates the phenotype of stromal cells and blocks the promoting effects of stromal cells on prostate cancer cell migration. Furthermore, decrease of IL-8 expression was observed in ginsenoside Rg3-treated stromal cells and down-regulation of IL-8 was essential for the anti-senescence role of ginsenoside Rg3. The research also uncovered that ginsenoside Rg3 attenuated IL-8 expression by damping ROS level and transcriptional activity of IL-8 gene promoter. In conclusion, our results suggested potential beneficial effects of ginsenoside Rg3 in prostate cancer treatment, by the targeting of the stromal component, especially in the senescent stromal environment.
RESULTS

Ginsenoside Rg3 prevented the senescence of prostate stromal cells in vitro
Senescence-associated β-galactosidase (SA-β-gal) is commonly used as a marker of cellular senescence. In this study, normal prostatic stromal cells WPMY-1, NAF, and carcinoma-associated fibroblasts (CAF) cells were cultured in DMEM medium supplemented with 0.5% fetal bovine serum (FBS) for 36 h and subsequently treated with vehicle (DMSO) or 25 μM ginsenoside Rg3 for another 48 h. In all 3 cell lines, cell percentages of SA-β-gal positive staining were significantly down-regulated by ginsenoside Rg3 treatment ( Figure 1A and 1B). Cell cycle arrest was also evaluated by flow cytometry analysis and the results showed that ginsenoside Rg3 promoted the transition of the cell cycle from G0/G1 to S phase in WPMY-1 normal stromal cells and CAF carcinoma-associated stromal cells ( Figure 1C ). Not only was the viability of WPMY-1 and NAF cells enhanced by ginsenoside Rg3, but also the proliferation of WPMY-1 ( Figure 1D and 1E). We also studied the effects of ginsenoside Rg3 on primary cultured rat prostate stromal cells and found that the compound not only inhibited the senescence of serum-starved cells but also delayed replicative senescence (Supplementary Figure 1) . All these results indicated that ginsenoside Rg3 is an anti-senescent compound in prostate stromal cells.
Ginsenoside Rg3 up-regulated the expression of the smooth muscle cell markers SM22 and smooth muscle myosin heavy chain (SMMHC) in WPMY-1 and NAF cells
The heterogeneity of prostate stromal cells has been widely characterized [12] . The cells mainly comprise fibroblasts and smooth muscle cells with diverse phenotypes. The phenotypic variation of prostate stromal cells has been observed in benign prostatic hyperplasia (BPH) and prostate cancer. In this research, immunofluorescence assays were performed to analyze phenotypic markers in WPMY-1 and NAF (Figure 2A Images of CAF were at ×200 magnification. The results were obtained from 3 independent experiments and are presented as means ± SD. *p < 0.05; **p < 0.01. conditioned medium (CM) collected from stromal cells treated with vehicle (CM-CTRL) or ginsenoside Rg3 (CM-Rg3) were used to treat PC3 prostate cancer cells for 24 h in wound-healing assays. CM-CTRL from WPMY-1 significantly promoted the migration of PC3 compared with DMEM-CTRL, while the pro-migratory activity of stromal cells could be reversed by ginsenoside Rg3 (Figure 3A and 3B) . Transwell assays were also performed to verify the results ( Figure 3C and 3D) . Moreover, other wound-healing assays demonstrated that ginsenoside Rg3 also blocked the promoting effects of NAF on cancer cell migration (Supplementary Figure 2) .
Ginsenoside Rg3 inhibited IL-8 expression in prostatic stromal cells
IL-8 has been reported as up-regulated in senescent fibroblast cells where it contributes to the establishment of a special senescence-associated secretion phenotype (SASP) [13] . In this research, the expression of several factors was detected in stromal cells treated with or without ginsenoside Rg3. IL-8 mRNA expression in WPMY-1 cells and the protein concentration in corresponding CM were significantly down-regulated in a time-dependent manner following treatment with Rg3 ( Figure discovered that depletion of IL-8 receptor CXCR2 delayed both replicative and oncogenic signal-induced senescence. However, other research has reported that IL-8 may prevent oxidative-stress-induced human endothelial cell senescence [15] . In our study, the plasmid PCDNA3.1-IL8 was constructed and transfected into WPMY-1 cells, and IL-8 over-expression was confirmed by measurement of the protein concentration in CM ( Figure 5A ). Overexpression of IL-8 reversed ginsenoside Rg3-decreased SA-β-gal positive staining in WPMY-1 cells, while transfection with empty plasmid PCDNA3.1 (+) had no impact on the effects of ginsenoside Rg3. Similarly, exogenous addition of IL-8 to WPMY-1 cells also blocked the anti-senescent role of ginsenoside Rg3 ( Figure 5B , 5C, and 5D). Also, the addition of IL-8 antagonized Rg3-inhibited NAF senescence (Supplementary Figure  3) . Furthermore, IL-8 addition reversed the damping role of ginsenoside Rg3 in WPMY-1 cell-induced cancer cell migration (Supplementary Figure 4) . These results suggested that IL-8 down-regulation was pivotal for ginsenoside Rg3-induced anti-senescence in prostate stromal cells. 
Ginsenoside Rg3 inhibited IL-8 expression by decreasing the cellular ROS level
The exact molecular mechanism of Rg3 downregulation of IL-8 expression was further explored. ROS, an indicator of cellular oxidative stress, has been reported to regulate IL-8 expression [16] , and ginsenoside Rg3 has been found to suppress LPS-or UV-irradiationinduced ROS levels in macrophage and in the keratinocyte cell line HaCaT [17] . In our study, ROS levels were significantly attenuated in WPMY-1 cells treated with ginsenoside Rg3 for 24 h, while the addition of H 2 O 2 blocked the regulatory effect of ginsenoside Rg3 on ROS level ( Figure 6A ). Additionally, IL-8 down-regulation induced by ginsenoside Rg3 was completely antagonized by the addition of H 2 O 2 ( Figure 6B and 6C). CoCl 2 , which was used to induce cell hypoxia, increased ROS in WPMY-1 cells, as well as blocked the regulatory effects of ginsenoside Rg3 on ROS level and IL-8 expression. However, the scavenger of ROS, N-acetyl-L-cysteine (NAC) was able to significantly down-regulate ROS levels and IL-8 protein expression in CoCl 2 -treated WPMY-1 cells (Supplementary Figure 5) .
Ginsenoside Rg3 attenuated the transcriptional activity of IL-8 gene promoter
Three luciferase reporter plasmids, including IL-8 promoter fragments with different lengths -IL-8 pro L (˗1481nt to +44nt), IL-8 pro M (˗765nt to +44nt), and IL-8 pro S (˗176nt to +44nt) -were transfected into WPMY-1 cells and then treated with DMSO or ginsenoside Rg3 for 36 h. The transcriptional activity of all 3 IL-8 promoter fragments was down-regulated by ginsenoside Rg3, suggesting that the regulatory sites responding to ginsenoside Rg3 treatment are located in the shortest fragment (˗176nt to +44nt) ( Figure 6D ). Three main transcription factors AP-1, C/EBP β, and NF-κB are able to bind to this fragment [18] . Each binding site on IL-8 pro S was mutated and the regulatory effects of ginsenoside Rg3 on transcriptional activity were completely blocked when C/EBP β or NF-κB binding site was mutated. Both AP-1 and NF-κB binding site mutation significantly decreased the basic transcriptional activity of IL-8 promoter ( Figure  6E) . A luciferase reporter plasmid (containing 4 NF-κB conserved motifs) was transfected into WPMY-1 cells, and ginsenoside Rg3 down-regulated both the basic and TNFα-enhanced luciferase activity significantly ( Figure 6F and Supplementary Figure 6) . Figure  6B) .
DISCUSSION
The accumulation of senescent cells has been demonstrated during organism aging [19] , which suggests that senescent cells may play a role in aging-associated disease, including prostate cancer. Cellular senescence seems to exhibit diverse effects on epithelial and stromal cells in prostate cancer [20, 21] . Senescence is considered to prevent normal prostate epithelial cells from neoplasia as epithelial senescence exists in BPH and prostate intraepithelial neoplasia but is rare in frank tumors [22] . Besides, elevated expression of the senescent marker β-galactosidase is associated with lower cancer stage and predicts reduced prostate specific antigen (PSA) recurrence within primary prostate tumor [23] . Although senescence in prostate epithelial cells is considered to be anti-tumorigenic, senescent stroma promotes cancer progression through the secretion of chemokines/cytokines and the remolding of extracellular matrix, providing a protumorigenic microenvironment.
Ginsenoside Rg3 has been reported to inhibit prostate cancer cell proliferation and migration, and enhance cancer cell sensitivity to chemotherapy. However, the effects of ginsenoside Rg3 on prostate stromal cells have not been clarified. Our research revealed the antisenescent effects of ginsenoside Rg3 through a decrease in SA-β-gal positive staining in prostatic stromal cells, both by incubation in low serum medium and by over-replication. Under serum starvation conditions, ginsenoside Rg3 promoted cell cycle transition to S phase from G0/G1 during which senescent cells were arrested [24] , down-regulated p21 expression ( Supplementary   Figure 1) , increased cell viability and proliferation, and inhibited stromal cell-induced cancer cell migration. In a replicative senescent model of primary cultured rat prostatic stromal cells, ginsenoside Rg3 decreased p21 expression and DNA damage, as indicated by the positive staining of γH2A.X that was observed in the replicative senescent stromal cells but not in cells treated with ginsenoside Rg3. Furthermore, no γH2A.X staining was observed in stromal cells incubated in serum starvation conditions. SM22 is a 22KD actin-binding protein mainly expressed in smooth muscle cells and is considered a marker of smooth muscle differentiation. SM22 can act as a cancer repressor by modulating the secretion of matrix metalloproteinase 9 (MMP9) or the AR signaling pathway [25, 26] . Another smooth muscle marker, SMMHC, is also reported to be down-regulated either in BPH or smooth muscle adjacent to prostate cancer sites [27, 28] . These results provide some clues about the phenotype of procarcinogenic stromal cells in the prostate. Our recent report also demonstrated the down-regulation of SM22 and SMMHC in carcinoma associated stromal cells [29] . Although the exact differentiation phenotype of senescent prostate stromal cells has not been fully identified, this research revealed an up-regulation of SM22 and SMMHC in ginsenoside Rg3-treated cells, indicating the compound may inhibit the pro-carcinogenic stromal phenotype.
Inflammatory factors, such as IL-6 and IL-8, contribute to cellular growth arrest and senescence [30, 31] . Our research evaluated the expression of several factors in ginsenoside Rg3-treated WPMY-1 cells and only down-regulation of IL-8 was observed (Supplementary Figure 7) . The role of IL-8 in cellular senescence is controversial. Medina et al. [32] pointed out that IL-8 is a facilitator of the outgrowth of endothelial cell senescence, while Shen et al. [15] highlighted the preventive role of IL-8 on oxidative stress-induced endothelial cell senescence. In our study, over-expression or exogenous addition of IL-8 completely reversed the inhibitory effects of ginsenoside Rg3 on the senescence of stromal cells incubated in low serum medium and on cancer cell migration induced by CM collected from stromal cells. These results identified IL-8 as the pivotal modulator in ginsenoside Rg3-prevented stromal cell senescence.
IL-8 has been reported as a potential therapeutic target in prostate cancer treatment [33] , while the regulatory model of IL-8 expression in prostate stroma has not been fully elucidated. Previous report has suggested that ROS and the NF-κB pathway are involved in IL-8 regulation [34] . In this research, ginsenoside Rg3 decreased ROS in stromal cells incubated in serum starvation conditions, while either H 2 O 2 or CoCl 2 up-regulated ROS levels and blocked the inhibitory effects of ginsenoside Rg3 on both ROS level and IL-8 expression. It was interesting that the ROS scavenger NAC, but not ginsenoside Rg3, was able to attenuate CoCl 2 -induced ROS increase and IL-8 expression. First, the results suggested that ROS has a regulatory role in IL-8 expression, as depletion of ROS by NAC downregulated IL-8 expression. Second, ginsenoside Rg3 and H 2 O 2 /CoCl 2 may have different regulatory mechanisms in ROS modulation. Cellular ROS is mainly generated by mitochondria and NADPH oxidases (NOXs). We found that Rg3 down-regulated the mRNA expression of NOX4 (Supplementary Figure 7) , which is one producer of ROS in cells [35] , while a recent research indicated that depleting of mitochondrial DNA in liver tumor cells impaired CoCl 2 induced ROS generation, which suggested mitochondria with intact function were essential in CoCl 2 induced ROS up-regulation [36] . However, the exact role of NOX4 in the ginsenoside Rg3 regulation of IL-8 expression and in cellular senescence needs further exploration. Our research also analyzed transcriptional activity of the IL-8 gene promoter and revealed ginsenoside Rg3 decreased the recruitment of C/ EBP β and p65 to their corresponding binding sites on the IL-8 promoter.
In conclusion, our study demonstrated that ginsenoside Rg3 prevented the senescence in prostate stromal cells, and inhibited cancer cell migration through a stromal-epithelial interaction. Ginsenoside Rg3 also decreased the IL-8 expression essential for inhibiting serum-starved stromal cell senescence. Decreased cellular ROS and attenuation of the binding of transcription factors C/EBP β and p65 to IL-8 promoter mediated the inhibitory effects of ginsenoside Rg3 on IL-8 expression. Recent reports indicate that chemotherapy may induce stromal cell senescence, contributing to the chemoresistance of cancer cells [37] and this may be a possible reason for clinical chemotherapy failure. The research results lead to the novel suggestion of targeting the senescent stromal microenvironment, and assist in objective assessment of the use of ginsenoside Rg3 in prostate cancer treatment.
MATERIALS AND METHODS
Cell culture and treatment
Normal prostate stromal cell line WPMY-1 (American Type Culture Collection, USA) was cultured in DMEM medium (Sigma, USA), supplemented with 5% FBS (Invitrogen, USA) and 1% penicillin/streptomycin (P/S, Hyclone, USA). NAF (Normal-associated fibroblast) and CAF (carcinoma-associated fibroblast) cells, supplied by the Department of Urology of Medical University of Innsbruck (Innsbruck, Austria), were cultured in DMEM medium supplemented with 10% FBS and 1% P/S. Prostate cancer cells PC3, supplied from the German Cancer Research Center (DKFZ) (Germany), were cultured in RPMI 1640 medium (Sigma, USA) supplemented with 1% P/S and 10% FBS. WPMY-1, NAF, and CAF cells were pre-incubated in DMEM medium supplemented with 0.5% FBS for 36 h followed by treatment with either vehicle (DMSO) or 25 μM ginsenoside Rg3 (YiFang S&T, China).
SA-β-gal staining
WPMY-1, NAF, and CAF cells were seeded into 6-well plates and treated with vehicle or ginsenoside Rg3 for 48 h. A commercial SA-β-gal staining kit (Beyotime Institute of Biotechnology, China) was used according to the manufacturer ' s instructions. Senescent cells were identified as blue-stained by standard light microscopy (Leica, Germany), and photographs were taken using a phase-contrast microscope. Six view fields were randomly selected and the percentage of positive stained cells was calculated. The results were expressed as mean ± standard deviation (SD).
Cell viability assays
WPMY-1 and NAF cells were treated with either vehicle or 25 μM ginsenoside Rg3 for 0, 24, and 48 h, respectively. 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (Sigma, USA) was added into the medium. Cell medium was discarded 2 h later and 250 μL DMSO was added into each well. The absorbance at 570 nm was measured with a microplate reader (BioTek, USA). The results were expressed as mean of triplicates ± SD.
Cell cycle analysis
WPMY-1 and CAF cells were treated with vehicle or ginsenoside Rg3 for 24 h. Flow cytometry assays were used to analyze the cell cycle as previously reported [38] . 
Immunofluorescence assays
Western blot
WPMY-1 and NAF cells were treated with vehicle or ginsenoside Rg3 for 72 h. Proteins of cell extracts were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride (PVDF) membranes. The membranes were incubated with antibodies against SM22, SMMHC, and GAPDH (KC-5G4, Kangchen, China) overnight at 2 -8 °C. Proteins were detected by appropriate secondary antibodies (goat anti-rabbit or goat anti-mouse) conjugated with horseradish peroxidase (Bio-Rad, USA) followed by enhanced chemiluminescence detection (Amersham, USA). The results were quantified with Image J software and expressed as mean of triplicates ± SD.
Wound-healing assays
WPMY-1 cells were treated with vehicle or ginsenoside Rg3 for 48 h. CMs were collected, centrifuged at 400 g for 5 min to remove the floating cells and normalized according to cell number and named CM-CTRL and CM-Rg3 respectively. Unconditioned mediums (unCMs) DMEM-CTRL and DMEM-Rg3 (incubated DMEM medium supplied with vehicle or 25 μM Rg3 in a cell incubator for 48 h) were used as control. PC3 cells were cultured with RPMI1640 medium containing 0.5% FBS for 24 h. Each well was scratched with disposable tips in the cell monolayer. Each CM or unCM was mixed with RPMI1640 supplemented with 0.5% FBS in a 1:2 ratio. PC3 cells were treated with each mixture for 24 h. Images were taken at 200 × magnification under a phasecontrast microscope (Leica, Germany). Image J software was used to analyze the relative migration distance. The results were expressed as mean of triplicates ± SD.
Transwell assays
A protocol for transwell assays was followed according to our previous report [29] . Results were obtained from 3 independent experiments and quantitative results expressed as mean ± SD.
RNA isolation and real time PCR
Total RNA was extracted using Trizol reagent (Invitrogen, USA). Reverse transcription was performed with a commercial reverse transcription kit (Promega, USA). Real-time polymerase chain reaction (PCR) was performed using the specific primers listed in Table 1 . The relative gene expression was determined using the comparative CT method and normalized to housekeeping gene hypoxanthine phosphoribosyltransferase 1 (HPRT).
Human IL-8 ELISA assays
CM was collected from WPMY-1 or NAF cells and centrifuged at 400 g for 5 min to remove the floating 
Plasmids and transfection
Human IL-8 cDNA fragment containing complete coding DNA sequence (CDS) region was obtained from the total RNA of WPMY-1 cells by reverse transcription and PCR amplification. The cDNA fragment was cloned into vector PCDNA3.1 (+) with the restriction enzymes BamH I and Xho I (Takara, Japan) and the over-expression plasmid was named PCDNA3.1-IL8. Human IL-8 gene promoter fragment (˗1481nt to +44nt) was amplified from genomic DNA isolated from WPMY-1. The fragment was cloned into PGL3-Basic plasmid with Kpn I and Bgl II (Takara, Japan) to construct the luciferase reporter plasmid IL-8 pro L (˗1481nt to +44nt). Another two sense primers were used to construct the other two luciferase reporter plasmids: IL-8 pro M (˗765nt to +44nt) and IL-8 pro S (˗176nt to +44nt). The primers are listed in Table 1 . The plasmid pNF-κB-luc was a luciferase reporter with 4 NF-κB motifs (Clontech, USA). Transfections were performed using Lipofectamine™2000 (Invitrogen, USA). Luciferase assays were performed as described previously [39] .
Exogenous IL-8 addition
WPMY-1/NAF cells were treated with vehicle, 25 μM ginsenoside Rg3, 10 ng/mL human IL-8 protein (GenScript, USA), and human IL-8 protein + Rg3. After 48 h, the cells were analyzed with SA-β-gal staining and the percentage of positive stained cells was calculated. The results were expressed as mean ± SD.
ROS level assays
WPMY-1 cells were treated with DMSO, 25 μM Rg3, 600mM H 2 O 2 (Solarbio, China) and Rg3+H 2 O 2 , respectively. After 24 h, an ROS assay kit (Beyotime institute of biotechnology, China) was used to evaluate ROS levels according to the protocol. The photographs were taken under a fluorescent microscope (Leica, Germany) at 200 × magnification.
In vitro mutagenesis of the AP-1, C/EBP β, and NF-κB binding sites
The AP-1, C/EBP β, and NF-κB binding sites on IL-8 promoter were mutated by PCR respectively. The luciferase reporter plasmid IL-8 pro S was used as the template and the primers are listed in Table 1 . The PCR products were digested by Dpn I (Takara, Japan) for 3 h and transferred into DH5α bacteria to obtain 3 corresponding mutated reporter plasmids, named as AP-1 mut, C/EBP mut, and NF-κB mut. Each mutagenesis was confirmed by DNA sequencing.
ChIP assays
WPMY-1 cells were treated with vehicle or ginsenoside Rg3 for another 24 h. ChIP assays were then performed as described previously [39] . C/EBP β (sc-150, Santa Cruz, USA) and p65 antibodies (ab7970, Abcam, UK) and control rabbit Igg (bs-0296P, Bioss, China) were used. The primers used in the ChIP assays are shown in Table 1 and the PCR product was 128 bp.
Statistical analysis
The results are expressed as mean ± SD. Significance was assessed using Student's paired t-test. P < 0.05 was considered significant and p < 0.01 highly significant.
